



Granules India Limited

11nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad-500 081. INDIA
Ph : +91-40-66760000, Fax : +91-40-23115145
E-mail : mail@granulesindia.com URL : www.granulesindia.com

Dated September 28th, 2012

The Manager
Listing Department
National Stock Exchange of India Limited
'Exchange Plaza', C-1, Block G,
Bandra-Kurla Complex, Bandra (E),
Mumbai – 400 051

Fax: 022 – 26598237/38

Kind Attn: the General Manager

Dear Sir,

Sub: Press Release

Symbol: GRANULES

Enclosed please find a Press Release titled “Granules India Awarded Outstanding Exports – Formulations Award 2011-12 by Pharmexcil”.

Kindly take the above information on record

Thanking you,

Yours faithfully,

FOR , GRANULES INDIA LIMITED


(SHIVANGI SHARMA)

Company Secretary &
Compliance Officer



Encl: as above

Press Release

Granules India Awarded Outstanding Exports – Formulations Award 2011-12 by Pharmexcil

Hyderabad, September 28, 2012: Granules India Ltd., a fast growing pharmaceutical manufacturing Company, announced it has received the Outstanding Exports - Formulations Award 2011-12 from Pharmexcil, the Pharmaceutical Export Promotion Council of India set up by the Ministry of Commerce & Industry, Govt. of India.

The award was given to Granules during the “India-Asia Pacific Pharma Business Meet” which was held at The Marriott Hotel in Hyderabad.

“We are honoured to be recognized by Pharmexcil for our contribution to the global pharmaceutical industry. Granules is focused on supplying our products to the world; due to our blend of quality and value, more than 95% of our material goes to the international market. In terms of volume, we are among the largest pharmaceutical exporters in India. Every minute, consumers use more than 100,000 tablets either made by us or using our material. Granules has grown twice as fast as the industry because we are one of the few Indian companies that has the ability to supply products throughout the pharmaceutical manufacturing value chain. We expect our export business to continue to grow due to our recent formulations expansion” said Mr. Krishna Prasad, Managing Director, Granules India Limited.

About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company’s global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Granules has the largest PFI facility in the world with an industry leading 6 ton batch size. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Granules has strengthened its advantages through its Operational Excellence (OE) department which looks at every step of the manufacturing process in order to gain efficiencies and has also implemented systems that have standardized quality and reduced variation. The Company’s OE program is regularly cited by MNCs as a “best in class” program and is the comparative advantage that lets Granules provide world-class quality products at a lower cost than its competitors. The adoption of the OE philosophy by Granules has earned it several recognitions including The Economic Times Manufacturing Excellence Awards 2011.

Caution Statement:

Certain statements made above may be “forward looking statements” within the meaning of applicable laws and regulations.

Contacts:

Rukmini Baxi/ Divya Balasubramaniam
Genesis Burson-Marsteller
+91 964 232 0044/ +91 9962560024
rukmini.baxi@bm.com/divya.bala@bm.com

